Bill Miller’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-164,998
Closed -$30M 89
2023
Q1
$30M Buy
164,998
+20,032
+14% +$3.83M 1.87% 27
2022
Q4
$28.5M Sell
144,966
-25,369
-15% -$5.44M 1.84% 27
2022
Q3
$38.3M Sell
170,335
-52,620
-24% -$10.7M 2.33% 23
2022
Q2
$28.2M Sell
222,955
-18,893
-8% -$2.17M 1.43% 28
2022
Q1
$30.7M Buy
241,848
+525
+0.2% +$59.1K 0.99% 35
2021
Q4
$31.6M Buy
241,323
+1,898
+0.8% +$245K 0.87% 39
2021
Q3
$29.3M Sell
239,425
-57,864
-19% -$6.68M 0.68% 42
2021
Q2
$33.9M Buy
297,289
+6,050
+2% +$707K 0.81% 41
2021
Q1
$35M Buy
+291,239
New +$33M 0.91% 42

Other funds holding KRTX

Bill Miller's KRTX Position: Q2 2023 in Review

Bill Miller sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 164,998 shares — an estimated $30M sold.

Bill Miller first reported a position in KRTX in Q1 2021 and held it in 9 quarters. The position peaked at $38.3M in Q3 2022. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Bill Miller reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Bill Miller sold 164,998 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $30M.
  • Bill Miller first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Bill Miller's Karuna Therapeutics, Inc. Common Stock position peaked at $38.3M in Q3 2022.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Miller Value Partners's 13F filing for Q2 2023, filed 14 Aug 2023.